P). The FDA-approved labeling recommends 50 mg/kg/dose IV every 8 hours regardless of weight.
Premature and Term Neonates 0 to 7 days
50 mg/kg/dose IV or IM every 12 hours.
For the treatment of gynecologic infections (e.g., endometritis, pelvic cellulitis, pelvic inflammatory disease (PID)).
Intravenous or Intramuscular dosage
Adults
1 to 2 g IV or IM every 8 hours for moderate to severe infections and 2 g IV every 6 to 8 hours for severe infections. The maximum dosage is 12 g/day. The CDC suggests that cefotaxime may be effective for inpatient, intravenous treatment of PID; however, there is decreased anaerobic activity as compared to cefoxitin/cefotetan. Additionally, for outpatient PID therapy, cefotaxime may be administered with oral doxycycline with or without oral metronidazole for 14 days.
Adolescents and Children weighing 50 kg or more
1 to 2 g IV or IM every 8 hours for moderate to severe infections and 2 g IV every 6 to 8 hours for severe infections. The maximum dosage is 12 g/day. The CDC suggests that cefotaxime may be effective for inpatient, intravenous treatment of PID; however, there is decreased anaerobic activity as compared to cefoxitin/cefotetan. Additionally, for outpatient PID therapy, cefotaxime may be administered with oral doxycycline with or without oral metronidazole for 14 days.
For the treatment of disseminated Lyme disease† (i.e., neuroborreliosis, carditis, recurrent/persistent arthritis).
NOTE: Cefotaxime is recommended as an alternative to ceftriaxone for the treatment of early Lyme disease with acute neurological disease, for the initial treatment of hospitalized patients with Lyme carditis, and for late manifestations of Lyme disease.
Intravenous and Intramuscular dosage
Adults
2 grams IV or IM every 8 hours for 2 to 4 weeks.
Infants, Children, and Adolescents
150 to 200 mg/kg/day IV or IM divided every 6 to 8 hours (Max: 6 g/day) for 2 to 4 weeks.
For the empiric treatment of enteric infections†, including acute gastroenteritis† and infectious diarrhea† in HIV-infected patients.
Intravenous dosage
Adults and Adolescents
1 g IV every 8 hours is recommended by clinical practice guidelines as an alternative in HIV-infected patients as empiric therapy for bacterial enteric infections pending definitive diagnosis.
For the treatment of severe leptospirosis† due to Leptospira sp.†.
Intravenous dosage
Adults and Adolescents
1 g IV every 6 hours for 7 days was as effective as IV penicillin G and doxycycline in an open-label, randomized comparative study.
For the treatment of acute bacterial sinusitis†.
Intravenous dosage
Adults
2 g IV every 4—6 hours for 5—7 days is recommended as alternative therapy by the Infectious Diseases Society of America (IDSA) in patients with severe infection requiring hospitalization.
Infants, Children, and Adolescents
100—200 mg/kg/day (Max: 12 g/day) IV divided every 6 hours for 10—14 days is recommended as alternative therapy by the Infectious Diseases Society of America (IDSA) in patients with severe infection requiring hospitalization.
For the treatment of salmonellosis† in HIV-infected patients.
Intravenous dosage
Adults and Adolescents
1 gm IV every 8 hours is recommended as an alternative therapy to a quinolone in the HIV guidelines. For patients with a CD4 count of 200 cells/mm3 or more, the duration of therapy is 7 to 14 days for patients without bact |
